PolyPid (NASDAQ:PYPD) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $14.00 price target on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.

PolyPid Stock Performance

PYPD opened at $5.00 on Wednesday. PolyPid has a 52 week low of $3.57 and a 52 week high of $13.48. The company has a debt-to-equity ratio of 2.17, a current ratio of 0.83 and a quick ratio of 0.83. The firm has a 50-day simple moving average of $4.96 and a two-hundred day simple moving average of $5.02.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($3.97) earnings per share for the quarter, missing the consensus estimate of ($2.17) by ($1.80). Equities analysts predict that PolyPid will post -3.72 EPS for the current year.

Hedge Funds Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. bought a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid makes up approximately 1.8% of Rosalind Advisors Inc.’s holdings, making the stock its 20th biggest holding. Rosalind Advisors Inc. owned 8.67% of PolyPid at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.